The effect of the JAK2 V617F mutation on PRV-1 expression.
JAK2(V617F)an acquired mutation of JAK2, is present in a majority of patients with polycythemia vera and to a lesser extent among patients with the other myeloproliferative disorders. We analyzed the effect of JAK2(V617F) on the expression of polycythemia rubra vera 1(PRV-1), using an in vitro model. Compared to wild-type JAK2, the presence of JAK2(V617F) increased both PRV-1 protein and mRNA levels in murine myeloid cells. A JAK2 inhibitor eliminated the V617F-induced increase in PRV-1 expression.
Mnjoyan
Zakar
Z
Yoon
Donghoon
D
Li
Jun
J
Delhommeau
François
F
Afshar-Kharghan
Vahid
V
D019943:Amino Acid Substitution / Q000235:genetics; D058851:GPI-Linked Proteins; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology; D006801:Humans; D007519:Isoantigens / Q000096:biosynthesis* / Q000235:genetics; D053614:Janus Kinase 2; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000235:genetics; D009154:Mutation; D010649:Phenylalanine / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000235:genetics; D015854:Up-Regulation / Q000235:genetics; D014633:Valine / Q000235:genetics
C407242:CD177 protein, human; D058851:GPI-Linked Proteins; D007519:Isoantigens; D008562:Membrane Glycoproteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D010649:Phenylalanine; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D014633:Valine